BioSpace News Archive

Kiromic BioPharma Reports Favorable Deltacel ™ Preclinical Pharmacology Results.

GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced its contributions to eight posters, one platform presentation and one symposium session to be released at the upcoming 2023 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting.

ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today provided an update to drug and medical device developments expected in 2023.

Longeveron Inc. today announced the appointment of seasoned global pharmaceutical leader Wa’el Hashad as Chief Executive Officer.

ContraFect Corporation announced that it has entered into a securities purchase agreement with a single institutional investor to purchase approximately $10.0 million of its common stock in a registered direct offering and warrants to purchase common stock in a concurrent private placement.

Verismo Therapeutics , a clinical-stage CAR T company, Penn spinout, and pioneer of the novel KIR-CAR platform technology, today announced a $7M pre-Series A financing round.

MyMD Pharmaceuticals, Inc.® (Nasdaq: MYMD) (“MyMD” or “the Company”) announced that preclinical data from a study, conducted in partnership with Charles River Laboratories International, Inc., has been accepted for presentation at the upcoming Society of Toxicology (SOT) 2023 Annual Meeting.

Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced that management will participate in the following upcoming investor conferences.

FSD Pharma Inc. today announced that iconic entrepreneur Kevin Harrington has joined the Company’s Advisory Board.

Jaguar Health today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) to crofelemer for the indication of microvillus inclusion disease (MVID).